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ABSTRACT
Purpose There is widespread concern about increases in antibiotic use, but comparative data from different European countries on rates of
use are lacking. This study was designed to measure and understand the variation in antibiotic utilization across ﬁve European countries.
Methods Seven European healthcare databases with access to primary care data from Denmark, Germany, the Netherlands, Spain and the
UK were used to measure and compare the point and 1-year-period prevalence of antibiotic use between 2004 and 2009. Descriptive analyses
were stratiﬁed by gender, age and type of antibiotic. Separate analyses were performed to measure the most common underlying indications
leading to the prescription of an antibiotic.
Results The average yearly period prevalence of antibiotic use varied from 15 (Netherlands) to 30 (Spain) users per 100 patients. A higher
prevalence of antibiotic use by female patients, the very young (0–9 years) and old (80+ years), was observed in all databases. The lowest
point prevalence was recorded in June and September and ranged from 0.51 (Netherlands) to 1.47 (UK) per 100 patients per day. Twelve
percent (Netherlands) to forty-nine (Spain) percent of all users were diagnosed with a respiratory tract infection, and the most common type
of antibiotic prescribed were penicillin.
Conclusion Using identical methodology in seven EU databases to assess antibiotic use allowed us to compare drug usage patterns across
Europe. Our results contribute quantitatively to the true understanding of similarities and differences in the use of antibiotic agents in differ-
ent EU countries. © 2015 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd.
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INTRODUCTION
Studies on antibiotic use in Europe have shown an
increase in the total volume of outpatient antibiotic
sales and reimbursements between 1997 and 2009.1,2
There are few studies that have measured the prescrip-
tion rates of antibiotic agents in different European
countries using healthcare databases with access to
primary care data, despite antibiotic agents being most
commonly prescribed by general practitioners.3,4
Whilst there has been an increase in the availability
and use of electronic healthcare data sets for drug
safety surveillance and pharmacoepidemiological
hypothesis testing studies, using information from
multiple databases for comparative purposes is challenging
due to heterogeneity between databases in structure,
terminology, underlying healthcare systems and data
capture.5–9 Comparing the rates of antibiotic drug pre-
scribing or dispensing between different countries
using patient data as recorded in electronic healthcare
data sets facilitates an understanding of the broad range
of reported incidences of adverse events associated
with the use of antibiotics, including hepatic injuries
and antibiotic resistance.10–13
The current study was designed to measure and un-
derstand the variation in antibiotic utilization across
speciﬁc databases as part of ‘Pharmacoepidemiological
Research on Outcomes of Therapeutics by a European
Consortium’ (PROTECT).14 The primary objective of
this study was to measure and to compare the point
and 1-year-period prevalence of general practice anti-
biotic prescriptions or dispensations between 2004
and 2009 in ﬁve different European countries using
seven healthcare databases. Additionally, this study
aimed to describe the most common underlying diag-
noses leading to the prescription of an antibiotic agent
and the proportional use of different types of antibiotic
agents per database and over time.
METHODS
Data sources
The analyses were conducted in patient populations
from the following databases: (i) the Clinical Prac-
tice Research Datalink (CPRD) from the UK; (ii)
The Health Improvement Network (THIN) from the
UK; (iii) the ‘Base de datos para la Investigación
Farmacoepidemiologica en Atencion Primaria’
(BIFAP) — a Spanish computerized database of
medical records of primary care; (iv) the Bavarian
Association of Statutory Health Insurance Physicians
(‘Kassenärztliche Vereinigung Bayerns’ [KVB]) da-
tabase (henceforth referred to as the Bavarian Claims
Database); (v) the Dutch Mondriaan Netherlands Pri-
mary Care Research Database (NPCRD); (vi) the
Dutch Mondriaan Almere Healthcare group (AHC)
database; and (vii) the Danish national registries.
The two UK general practice databases, CPRD and
THIN, collect and archive the electronic medical
records of more than 5 and 3million active patients,
respectively, covering over 8% of the UK population
(Table 1).5,6,15 The UK databases overlap to some
extent, but in 2012, they provided unique information
for 268 and 168 practices, respectively.16 The BIFAP
Table 1. Details of seven electronic health care databases with access to primary care data
Database Country Cumulative
population
number
(2008)
Active
population
number
(2008)
Start data
availability
Data
source
Coding
diagnoses
Coding
drugs
Exposure Contribution
CPRD UK 11m 3.6m 1987 GP READ BNF Prescriptions All
THIN UK 7.8m 3.1m 2003 GP READ BNF Prescriptions No
seasonality
BIFAP Spain 3.2 m 1.6m 2001 GP ICPC ATC Prescriptions All
Bavarian Claims
Database
Germany 10.5 m 9.5m 2001 Claims ICD ATC Dispensations No
seasonality
Mondriaan NPCRD The
Netherlands
500 000 300 000 1991 GP ICD/ICPC ATC Prescriptions All
Mondriaan AHC The
Netherlands
200 000 150 000 1991 Multi-
source
ICD/ICPC ATC Dispensations All
The Danish,
DKMA managed,
national databases
Denmark 5.2 m 5.2 1994 (medical
product)1979
(patient
register)
Multi-
source
ICD ATC Dispensations No
prevalence
by type
GP, General Practice; BNF, British National Formulary; ICPC, International Classiﬁcation of Primary Care; ATC, Anatomical Therapeutic Chemical Classi-
ﬁcation System; ICD, International Classiﬁcation of Diseases; m, million; CPRD, Clinical Practice Research Datalink; THIN, The Health Improvement Net-
work; BIFAP, Base de datos para la Investigacion Farmacoepidemiologica en Atencion Primaria; NPCRD, Netherlands Primary Care Research Database;
AHC, Almere Healthcare group; DKMA, Danish Health and Medicines Authority.
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database, covering around 6.8% of the Spanish popu-
lation, collects data from both GPs and paediatricians
and currently has 1190 collaborating physicians from
9 different autonomous communities in Spain.7 Data
from the Bavarian Claims Database are extracted from
the Bavarian Association of Statutory Health Insur-
ance Physicians accounting system.17 The German
database includes population-based data on diagnoses
and medical services linked to outpatient treatment
data through GPs and specialists. The Dutch
Mondriaan project links data from various sources
(pharmacy, GP and hospital pharmacy/laboratory).
For the purposes of the current study, two different pri-
mary care databases within the Mondriaan project
were used: the NPCRD and the AHC database.9 The
Danish national registries, managed by the Danish
Health and Medicines Authority (DKMA), contain in-
formation on hospital contacts, medication dispensing
on a pharmacy level linked to individuals who
redeemed the prescription, causes of death for the en-
tire population and contact information of visits to
GPs as well as specialists in private care.18
Study population and period of valid data collection
The source population in all ﬁve countries included all
individuals with access to primary health care.
As primary care is free at the point of delivery, it
has almost universal coverage in the UK, Denmark,
the Netherlands, Germany and Spain. Primary care
physicians are gatekeepers to specialist care and
are usually the ﬁrst healthcare contact for all non-
emergency care. After registration, a general practice
becomes the typical source of care. In most European
countries, the choice of general practice is dependent
on geographical proximity to the primary address of
an individual.
The study population in every database was com-
posed of all available patients of all ages with an active
registration status during the study period of 1 January
2004 to 31 December 2009. In the Dutch Mondriaan
AHC and the Bavarian Claims Database, the last avail-
able year of data collection was 2008. The remaining
databases ended data collection in December 2009.
Valid data collection started a year after the date when
a practice became up to research quality standard or
the date when a patient enrolled into a practice or the
date that a practice was enrolled into the database,
whichever came last. The follow-up time of patients
was censored on the date a patient died, the date a pa-
tient was transferred out of the practice, the end of the
database’s data collection or the date that the practice
left the database, whichever came ﬁrst.
Exposure deﬁnition
Exposure was deﬁned as a recorded prescription for an
antibiotic agent listed in chapter 5 of the British Na-
tional Formulary or therapeutic subgroup J01 of the
Anatomical Therapeutic Chemical (ATC) Classiﬁca-
tion System. In the Danish, Bavarian and Mondriaan
AHC databases, exposure was deﬁned as the dispens-
ing of an antibiotic agent to a registered individual.
Prescriptions for topical antibiotics were excluded.
Antibiotic agents were grouped in seven categories:
tetracyclines, penicillins, cephalosporins, macrolides,
aminoglycosides, quinolones and other antibiotics
(sulphonamides and other combinations). To assess
the point prevalence of antibiotic use, duration of ex-
posure was calculated by dividing the total quantity
of prescribed or dispensed antibiotics by the numeric
daily dosage prescribed or dispensed. The mode
(BIFAP only) or median duration of exposure to all
antibiotic agents was imputed when information on
the total quantity or the prescribed daily dosage was
missing. The total number of patients registered in
every database was based on the total active annual
patient population at mid-year from 2004 to 2009.
Calculation of period and point prevalence
Annual 1-year-period prevalence was calculated by
dividing the number of patients being prescribed an an-
tibiotic in the study period of interest (numerator) by
the number of patients available in every database at
mid-year (denominator). Antibiotic users were deﬁned
as patients with at least one recorded antibiotic pre-
scription or dispensation. Crude prevalence rates and
prevalence rates standardized by age and sex were
calculated to account for potential differences in the
age–sex distribution of the different populations across
databases and over time. We applied direct standardi-
zation according to the 2008 European population stan-
dard.19 We quantiﬁed time trends in prevalence per
database using Poisson regression. Separate analyses
were performed to assess 1-year-period prevalence
rates (2004–2009) of antibiotic drug use stratiﬁed by
indication and gender in all databases. Indications for
antibiotic agents were classiﬁed into the following
three main groups: (i) respiratory infections; (ii) genito-
urinary tract infections; (iii) other infections; and (iv)
unknown (for code lists, see Supporting Information).
The latter category included patients with more than
one of the aforementioned indications for the receipt
of one antibiotic prescription. An indication for an an-
tibiotic agent was assessed by searching for speciﬁc
computer codes for infections within 2weeks prior to
or on the date of the ﬁrst prescription in the year of
antibiotic use: a methodological comparison
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interest. In the Bavarian Claims Database, diagnoses
were linked to prescriptions if the prescription was dis-
pensed in the quarter of the recorded underlying diagno-
sis. Additional free text information to link prescriptions
to indications was only used in the BIFAP database.
Separate analyses were performed to assess 1-year-
period prevalence of antibiotic drug use stratiﬁed by
major antibiotic groups and by yearly number of prescrip-
tions per patient (1, 2–4, 5–10 and ≥11 prescriptions).
Point prevalence was assessed in the CPRD,
BIFAP, DKMA and both Mondriaan databases on
the 1st of March, June, September and December
from 2004 to 2009 to take seasonal variations into ac-
count. For this analysis, antibiotic use was deﬁned as
having received a prescription/dispensation for an an-
tibiotic agent before or on the 1st of March, June,
September and December that lasted until or after
the 1st of the same month.
RESULTS
Overall comparison of antibiotic use
The highest crude prevalence of antibiotic use was ob-
served in the BIFAP, DKMA, CPRD and THIN data-
bases, with an average annual prevalence of 30 users
per 100 patients in the Spanish and Danish databases
and 29 users per 100 patients in the UK databases
(Figure 1). The lowest annual prevalence of antibiotic
use was observed in one of the Dutch databases
(Mondriaan NPCRD: 15 users per 100 patients). When
the prevalence of antibiotic use was adjusted for age
and sex, the highest prevalence of antibiotic use was
still observed in the Spanish and Danish databases
(31 users per 100 patients), followed by the UK data-
bases (29 users per 100 patients). The lowest adjusted
annual prevalence of antibiotic use was observed in
the Dutch Mondriaan NPCRD and AHC databases
(16 and 22 users per 100 patients, respectively)
The yearly period prevalence of antibiotic users was
relatively stable between 2004 and 2009. The results
from the Poisson regression model showed no evi-
dence of a clear time trend.
The lowest-point prevalence of antibiotic use in
the CPRD, BIFAP, Mondriaan and DKMA data-
bases was recorded in the summer months (June
and September). The seasonal difference in the number
of prescriptions was more pronounced in BIFAP than
in other databases, with an average increase of 42%
in the proportion of patients who were prescribed an
antibiotic in December and March compared with June
and September (Figure 2).
Comparison of the prevalence of antibiotic
prescriptions by age
A higher annual prevalence of antibiotic use by female
patients was observed in all databases (Table 2). Anti-
biotic use stratiﬁed by age groups showed a similar
Figure 1. Comparison of the annual prevalence of antibiotic use (2004–2009) in seven European health care databases (crude and age/sex standardized).
CPRD, Clinical Practice Research Datalink; THIN, The Health Improvement Network; BIFAP, Base de datos para la Investigacion Farmacoepidemiologica
en Atencion Primaria; NPCRD, Netherlands Primary Care Research Database; AHC, Almere Healthcare group; DKMA, Danish Health andMedicines Authority
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pattern in all seven databases. Antibiotic prescribing
was highest in the very young (0–9years) and very
old (80+years) patient populations and relatively sta-
ble from 10 to 59years (Figure 3).
Comparison of the prevalence of antibiotic use by
underlying diagnoses
For a large proportion of antibiotic users, there were no
known or multiple indications recorded within 2weeks
prior to or on the day of the ﬁrst prescription. Of those
patients for whom an indication was found in CPRD,
THIN, BIFAP and the Bavarian Claims Database, a re-
cording of a respiratory tract infection was the most
common diagnosis (Table 2). In the Danish and Dutch
Mondriaan NPCRD databases, most patients were di-
agnosed with an infection other than respiratory tract
or genitourinary. In all databases, female antibiotic
users were more often identiﬁed with a diagnosis of
genitourinary tract infections than males.
Comparison of the prevalence of antibiotic use by type
and number of prescriptions
The most common type of antibiotic drug class pre-
scribed in every database was penicillins. Macrolides
were the second most prescribed type of antibiotic
agent in the British and Spanish databases. In the
Dutch databases, the second most common class of an-
tibiotics prescribed were tetracyclines. By comparison,
Figure 2. Point prevalence of antibiotic use (2004–2009) in ﬁve European health care databases. CPRD, Clinical Practice Research Datalink; BIFAP, Base de
datos para la Investigacion Farmacoepidemiologica en Atencion Primaria; NPCRD, Netherlands Primary Care Research Database; AHC, Almere Healthcare
group; DKMA, Danish Health and Medicines Authority
Table 2. Primary diagnosis of antibiotic users in ﬁve European databases stratiﬁed by gender (2008)
Database Gender (ratio) Respiratory tract infections Genitourinary infections Other infections Unknown
CPRD
Males (1) 175 039 (35%) 13 508 (3%) 6415 (1%) 303 174 (61%)
Females (1.5) 242 755 (33%) 58 416 (8%) 9078 (1%) 432 408 (58%)
THIN
Males (1) 153 679 (36%) 23 225 (5%) 14 870 (3%) 237 398 (55%)
Females (1.49) 231 267 (35%) 105 685 (16%) 25 941 (4%) 288 780 (44%)
BIFAP
Males (1) 93 283 (52%) 8999 (5%) 15 311 (8%) 63 719 (35%)
Females (1.19) 117 258 (46%) 35 333 (14%) 16 661 (7%) 83 986 (33%)
Bavarian Claims Database
Males (1) 599 615 (52%) 76 265 (7%) 87 727 (8%) 383 813 (33%)
Females (1.24) 700 883 (42%) 305 663 (18%) 105 546 (6%) 553 215 (33%)
Mondriaan NPCRD
Males (1) 6292 (14%) 1323 (3%) 9827 (22%) 27 169 (61%)
Females (1.57) 8030 (10%) 8016 (10%) 14 406 (18%) 48 485 (62%)
Mondriaan AHC
Males (1) 4455 (22%) 1090 (6%) 2930 (15%) 11 400 (57%)
Females (1.52) 5918 (17%) 7557 (22%) 3746 (11%) 16 995 (50%)
DKMA
Males (1) 34 083 (11%) 15 819 (5%) 176 838 (55%) 92 957 (29%)
Females (1.37) 42 754 (10%) 82 870 (19%) 202 871 (46%) 114 640 (26%)
CPRD, Clinical Practice Research Datalink; THIN, The Health Improvement Network; BIFAP, Base de datos para la Investigacion Farmacoepidemiologica en
Atencion Primaria; NPCRD, Netherlands Primary Care Research Database; AHC, Almere Healthcare group; DKMA, Danish Health and Medicines Authority.
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the number of tetracyclines prescribed in the UK relative
to the number of patients in the database was much
smaller, whilst the relative number of cephalosporins
prescribed was much higher than in the Dutch
Mondriaan databases. In the German database, quino-
lones were the second most prescribed type of
antibiotic class, whilst they were one of the least
prescribed types of antibiotic in most other databases
(Figure 4). In every database, the relative number of pre-
scriptions for penicillins and quinolones was higher in
2008 compared with that in 2004. The use of tetracy-
clines and macrolides had also increased in almost every
database, except BIFAP. Prescriptions for cephalosporins
increased in the Dutch and German databases, but not in
the other databases.
Most antibiotic-using patients, 81% in Mondriaan
NPCRD, 67% in Mondriaan AHC, 57% in CPRD
and 60% in THIN and BIFAP, received only one anti-
biotic prescription per year between 2004 and 2009. In
Mondriaan NPCRD, 18% received two to four pre-
scriptions per year, compared with 30% in Mondriaan
AHC and 35% in the UK and Spanish databases. Very
few patients (less than 3% in the Dutch databases and
less than 6% in the UK and Spanish databases) re-
ceived more than ﬁve prescriptions per year (Figure 5).
DISCUSSION
Summary. In this study, seven different European
electronic healthcare databases with access to
Figure 3. Comparison of 1-year-period prevalence of antibiotic use (2008) in seven European databases by age*. CPRD, Clinical Practice Research Datalink;
THIN, The Health Improvement Network; BIFAP, Base de datos para la Investigacion Farmacoepidemiologica en Atencion Primaria; NPCRD, Netherlands
Primary Care Research Database; AHC, Almere Healthcare group; DKMA, Danish Health and Medicines Authority
Figure 4. Proportional use of different types of antibiotic agents over time in six European databases in 2004 and 2008. CPRD, Clinical Practice Research
Datalink; THIN, The Health Improvement Network; BIFAP, Base de datos para la Investigacion Farmacoepidemiologica en Atencion Primaria; NPCRD,
Netherlands Primary Care Research Database; AHC, Almere Healthcare group; DKMA, Danish Health and Medicines Authority
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primary care data from Denmark, Germany, the
Netherlands, Spain and the UK were used to compare
the annual period prevalence of antibiotic use be-
tween 2004 and 2009. The yearly prevalence of
crude and standardized antibiotic use was similar
across databases, ranging from 26 (Germany) to 31
(Spain) users per 100 patients, with the exception of
the Netherlands. The lowest average annual preva-
lence was observed in the Dutch Mondriaan NPCRD
database: 16 users per 100 patients. There were sim-
ilar patterns of antibiotic use across all databases with
regard to gender, age and seasonality. Across all da-
tabases, most patients received only one prescription
in any given year. National preferences for types of
antibiotics prescribed, after penicillin, strongly dif-
fered per country.
Our results are similar to studies using sales and re-
imbursement data to compare rates of antibiotic use in
Europe. When limited to the ﬁve countries that we
included in our study, the European Surveillance of
Antimicrobial Consumption (ESAC) project found the
lowest antibiotic prescription rate in the Netherlands,
followed by Germany. Danish and UK prescription
rates were similar, and Spanish prescription rates were
among the highest.1 The ESAC project reported the
same antibiotic prescription trends over time. Our re-
sults are also in line with other studies that show there
is more seasonal variability in antibiotic use in Spain
compared with the UK and the Netherlands.1
Implications for research and practice. The implica-
tions for future pharmacoepidemiological research on
antibiotics are twofold:
(1) Our main ﬁndings show that the prevalence of anti-
biotic use in ﬁve European countries is very similar,
with the exception of the Netherlands. The preva-
lence of antibiotic use in the Netherlands is not only
lower compared with the prevalence in other coun-
tries, but most individuals that received an antibiotic
agent only received a single antibiotic prescription
in any given year (81%), which suggests that the
prescribing behaviour of physicians is highly effec-
tive. Whilst we did not set out this descriptive study
to ﬁnd the best-case scenario of antibiotic use, we
believe that research using Dutch electronic health
records could produce reliable estimates of the most
conservative absolute estimates of adverse events
associated with the use of antibiotics, including he-
patic injuries and antibiotic resistance.
(2) Whilst variability in the overall prevalence of anti-
biotic use was minimal across the UK, Spain,
Denmark and Germany, there were differences in
the recorded clinical indications for use and the in-
tensity of use and clear differences in preferences
for antibiotic classes between the countries. In
studies investigating antibiotic-induced injuries,
the absence of recorded indications would restrict
effective stratiﬁcation by indication. Moreover,
differences in preferences for individual antibiotic
classes likely indicate signiﬁcant differences in the
composition of comparison groups.
Strengths and limitations. To our knowledge, this is
the ﬁrst study to measure and compare the prevalence
of antibiotic use as recorded on a patient level in dif-
ferent European healthcare databases with access to
primary care data. The primary strength of this study
Figure 5. Proportional number of prescriptions/dispensings per individual across ﬁve databases in 2008. CPRD, Clinical Practice Research Datalink; THIN,
The Health Improvement Network; BIFAP
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was the inclusion of the entire source population in
every database. DKMA data (Denmark) represent
complete quantitative national ﬁgures. Comparisons
with national statistical data have shown that the
CPRD, THIN and Mondriaan NPCRD databases are
generalizable to the UK and Dutch populations, re-
spectively.20–22 The data collected and archived in
the BIFAP database are demographically representa-
tive of the Spanish population, whilst data are not
collected from all autonomous communities in Spain.
As the electronic primary care record is used to gen-
erate patient prescriptions in all participating coun-
tries, medication data are complete and accurate.
All seven partners used a single protocol and shared
code lists to identify different types of antibiotic agents
and underlying diagnoses. For some databases, dis-
pensing records rather than prescription data were
used, which may have affected the measured differ-
ences in prevalence of antibiotic use between the
databases. For example, a small proportion of the dis-
pensing data may have included antibiotic prescriptions
prescribed by health care providers other than the
regular primary care physicians, such as prescriptions
received from dentists for emergency dental care. Dif-
ferent coding systems to measure prescriptions in every
database (British National Formulary versus ATC
codes) could also have caused some variability in the in-
clusion of some combinations of antibiotic agents.
We were not be able to detect patients who were pre-
scribed or dispensed antibiotic agents outside primary
care (i.e. in a hospital, by private doctors or by over-
the-counter sales24,25), and we were not able to conﬁrm
whether a patient actually took the drug. Therefore, the
data may not represent the true use of antibiotics by the
population. If information on duration of antibiotic use
was missing, we imputed the median value of the dura-
tion of all other exposures, but acknowledge that this
speciﬁc technique to impute missing values may have
led to an underestimation or overestimation of duration
of exposure in a very small group of antibiotic users.
The point prevalence of antibiotic use may have been
affected by some misclassiﬁcation as for those patients
with missing information the median duration of other
prescriptions/dispensations was imputed. This may
explain why in Figure 2, the recorded antibiotic use
in CPRD is higher than in BIFAP, in contrast with
Figure 1. Figure 2 is also affected by the choice of
months to estimate seasonality. For instance, in Spain,
the month with the lowest antibiotic consumption is
August and the highest consumption is usually re-
corded in December, January or February, depending
on the timing of ﬂu epidemics.25
A limitation of the current study was that the use of
antibiotic agents could not be directly linked to poten-
tial underlying diagnoses. In most databases, an indica-
tion for an antibiotic agent was assessed by computer
search using speciﬁc codes, or free text when available,
within 2weeks prior to or on the date of the ﬁrst
prescription/dispensation in the year of interest. Preva-
lence of antibiotic use linked to underlying diagnoses
was investigated in all seven databases using either
International Classiﬁcation of Diseases, International
Classiﬁcation of Primary Care or READ codes. Despite
efforts to maximize comparability of the three different
coding systems, there may have been some variability
in the inclusion of underlying diagnoses. However,
some of the differences inmain indications for antibiotic
use can be explained by differences in national guide-
lines for prescribing. For example, in the Netherlands,
GPs are actively discouraged from prescribing antibiotic
agentswhen patients experience uncomplicated respiratory
tract infections, which may explain the low number of
exposed patients with recorded respiratory tract infec-
tions in the Netherlands.23,24
There were some differences in the annual
prevalence of antibiotic agents between different
databases within the same country (the UK and the
Netherlands). The differences between the UK data-
bases were very small. The differences in the Dutch
data could be explained by the fact that the Mondriaan
AHC data were collected in a single city (Almere) with
a relatively young population, whereas the Mondriaan
NPCRD comprises a national sample of GPs.
Conclusions. As healthcare databases are increasingly
being used to conduct drug utilization studies and
pharmacoepidemiological investigations, including
studies that link the use of antibiotics to several health-
related outcomes, we believe that our results contribute
quantitatively to the true understanding of the use of an-
tibiotic agents in primary care in different EU countries.
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KEY POINTS
• Despite heterogeneity between seven European
electronic health care databases in structure,
terminology, underlying healthcare systems and
data capture, we found relatively stable and
similar yearly prevalence rates of crude and stan-
dardized antibiotic use between 2004 and 2009,
with the exception of the Netherlands.
• There were clear differences in preference for
antibiotic classes, recorded clinical indications
for use and intensity of use between the ﬁve
European countries in this study, which has
implications for comparative studies investigat-
ing antibiotic-induced injuries.
• The low prevalence rate of antibiotic use in the
Netherlands in combination with the low inten-
sity of use suggests that Dutch electronic health
records could produce reliable estimates of the
most conservative absolute estimates of adverse
events associated with the use of antibiotics.
ETHICS STATEMENT
The protocol was approved by the Spanish Agency for
Medical products (AEMPS) to be performed in the
BIFAP database as part of the PROTECT project and
was registered in the ENCePP electronic register of
studies (http://www.encepp.eu/encepp/studiesDatabase.
jsp). CPRD ISAC approval for the study was obtained
inOctober 2011 (11_019A_2).Wemaintained a blinding
procedure until the ﬁnal results from both CPRD and
BIFAP were submitted to the coordinating centre at
Utrecht University.
ACKNOWLEDGEMENTS
The research leading to these results was conducted as
part of the PROTECT consortium (Pharmacoepide-
miological Research on Outcomes of Therapeutics by
a European ConsorTium, www.imi-protect.eu) which
is a public–private partnership coordinated by the
European Medicines Agency.
Authors would like to thank the excellent collabora-
tion of physicians in the participating countries, whose
contribution in recording their professional practice
with high-quality standards makes possible the avail-
ability of databases used in this research.
The PROTECT project has received support from
the Innovative Medicines Initiative Joint Undertaking
(IMI JU) (www.imi.europa.eu) under Grant Agree-
ment no. 115004, the resources of which are
composed of ﬁnancial contributions from the
European Union’s Seventh Framework Programme
(FP7/2007-2013) and EFPIA companies’ in-kind
contribution. As a special form of the IMI JU grant,
Utrecht University and the University of Alcalá
received a direct ﬁnancial contribution from Pﬁzer
and Astra-Zeneca, respectively.
REFERENCES
1. Adriaenssens N, Coenen S, Versporten A, et al. European Surveillance of
Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe
(1997–2009). J Antimicrob Chemother. Dec 2011; 66Suppl 6: vi3–12.
2. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use
in Europe and association with resistance: a cross-national database study.
Lancet. Feb 12–18 2005; 365(9459): 579–587.
3. Molstad S, Lundborg CS, Karlsson AK, Cars O. Antibiotic prescription rates
vary markedly between 13 European countries. Scand J Infect Dis 2002; 34(5):
366–371.
4. Bjerrum LMA, Reutskiy A, Llor C, Cots JM, Caballero L, Ovhed I, Strandberg E,
Radzeviciene R, Gahrn-Hansen B. Respiratory tract infections in general practice:
total results 2008/2009 from 6 countries and 618/511 GPs. 2010. http://www.
happyaudit.org/ﬁles/pub/4398.pdf. Accessed December 17, 2012.
5. Clinical Practice Research Datalink. Observational data. http://www.cprd.com/
ObservationalData/CodedData.asp#Primarycare. Accessed December 17, 2012.
6. The Health Improvement Network (THIN). http://www.thin-uk.com. Accessed
December 17, 2012.
7. Salvador Rosa A, Moreno Perez JC, Sonego D, Garcia Rodriguez LA, de Abajo
Iglesias FJ. The BIFAP project: database for pharmaco-epidemiological research
in primary care. Aten Primaria. Dec 2002; 30(10): 655–661.
8. Wirtz K, Tauscher M, Zwerenz M, Munte A. Data warehousing for Bavarian out-
patient public health. http://subs.emis.de/LNI/Proceedings/Proceedings91/GI-
Proceedings-91-23.pdf. Accessed December 17, 2012.
9. Project Mondriaan. http://www.projectmondriaan.nl. Accessed December 17, 2012.
10. de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clini-
cally relevant drug-induced liver injury: a population based case–control study.
Br J Clin Pharmacol Jul 2004; 58(1): 71–80.
11. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and
outcomes from a prospective study of drug-induced liver injury in the United
States. Gastroenterology. Dec 2008; 135(6): 1924–1934, 1934 e1921-1924.
12. Ibanez L, Perez E, Vidal X, Laporte JR. Prospective surveillance of acute serious
liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemi-
ological and clinical features, and exposure to drugs. J Hepatol Nov 2002; 37(5):
592–600.
13. Antimicrobial ECDC. Resistance and healthcare-associated infections pro-
gramme. Antibiotic resistance in Europe: the challenges ahead. Euro Surveill
2009; 14(45): 1–2.
14. The Pharmacoepidemiological Research on Outcomes of Therapeutics by a
European Consortium (PROTECT). Objectives of PROTECT. http://www.imi-
protect.eu/objectives.html . Accessed December 17, 2012.
15. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and valid-
ity of diagnoses in the General Practice Research Database: a systematic review.
Br J Clin Pharmacol Jan 2010; 69(1): 4–14.
16. Cai B, Xu W, Bortnichak E, Watson DJ. An algorithm to identify medical
practices common to both the General Practice Research Database and The
Health Improvement Network database. Pharmacoepidemiol Drug Saf Jul 2012;
21(7): 770–774.
17. Kassenärztliche Vereinigung Bayerns (KVB). The Bavarian Association of
Statutory Health Insurance Physicians. http://www.kvb.de/ﬁleadmin/kvb/
dokumente/UeberUns/KVB-About-us.pdf. Accessed December 17, 2012.
18. Danish Health and Medicines Authority (DKMA). http://www.sst.dk/English.
Accessed December 17, 2012.
19. European Commission. Database: population on 1 January by age and sex. http://
epp.eurostat.ec.europa.eu/portal/page/portal/population/data/database. Accessed
December 17, 2012.
20. Nederlands Instituut voor onderzoek naar de gezondheidszorg (NIVEL).
Representatiteit van LINH (representativeness of LINH). http://www.nivel.nl/
representativiteit-van-linh. Accessed December 17, 2012.
21. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of the Health Im-
provement Network (THIN) database: demographics, chronic disease prevalence
and mortality rates. Inform Prim Care 2011; 19(4): 251–255.
22. Lawson DH, Sherman V, Hollowell J. The General Practice Research Database.
Scientiﬁc and Ethical Advisory Group QJMJun 1998; 91(6): 445–452.
antibiotic use: a methodological comparison
© 2015 The Authors. Pharmacoepidemiology and Drug Safety
published by John Wiley & Sons Ltd.
Pharmacoepidemiology and Drug Safety (2015)
DOI: 10.1002/pds
23. Verlee L, Verheij TJ, Hopstaken RM, Prins JM, Salome PL, Bindels PJ. [Sum-
mary of NHG practice guideline ‘Acute cough’]. Ned Tijdschr Geneeskd 2012;
156(0): A4188.
24. Onnouw EGJ. Kwaliteitstoetsing van huisartsenposten: Worden de NHG
standaarden ten aanzien van antibiotica gebruik nageleefd? Nijmegen:
Medicine, UMC St Radboud, 2007.
25. Lazaro-Bengoa E, Iglesias FJ, Lopez-Navas A, Fernandez-Cortizo MJ. Use of
antibiotics in Spain and regulatory framework for clinical development in the
European Union. Enferm Infecc Microbiol Clin Nov 2010; 28(Suppl 4): 10–16.
SUPPORTING INFORMATION
Additional supporting information may be found in the
online version of the article at the publisher's web site.
r. brauer et al.
© 2015 The Authors. Pharmacoepidemiology and Drug Safety
published by John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety (2015)
DOI: 10.1002/pds
